Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

CD371 cell surface expression: a unique feature of DUX4-rearranged acute lymphoblastic leukemia.

Schumich A, Zaliova M, Fortschegger K, Nebral K, Attarbaschi A, Fiser K, Kauer MO, Popitsch N, Haslinger S, Inthal A, Buldini B, Basso G, Bourquin JP, Gaipa G, Brüggemann M, Feuerstein T, Maurer-Granofszky M, Panzer-Grümayer R, Trka J, Mann G, Haas OA, Hrusak O, Dworzak MN, Strehl S.

Haematologica. 2019 Aug;104(8):e352-e355. doi: 10.3324/haematol.2018.214353. Epub 2019 Jan 31. No abstract available.

2.

Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.

Schumich A, Maurer-Granofszky M, Attarbaschi A, Pötschger U, Buldini B, Gaipa G, Karawajew L, Printz D, Ratei R, Conter V, Schrappe M, Mann G, Basso G, Dworzak MN; AIEOP-BFM-ALL-FLOW-Study Group.

Pediatr Blood Cancer. 2019 May;66(5):e27590. doi: 10.1002/pbc.27590. Epub 2018 Dec 18.

PMID:
30561169
3.

Linking cell function with perfusion: insights from the transcatheter delivery of bone marrow-derived CD133+ cells in ischemic refractory cardiomyopathy trial (RECARDIO).

Bassetti B, Carbucicchio C, Catto V, Gambini E, Rurali E, Bestetti A, Gaipa G, Belotti D, Celeste F, Parma M, Righetti S, Biava L, Arosio M, Bonomi A, Agostoni P, Scacciatella P, Achilli F, Pompilio G.

Stem Cell Res Ther. 2018 Sep 14;9(1):235. doi: 10.1186/s13287-018-0969-z.

4.

Flow cytometry for minimal residual disease testing in acute leukemia: opportunities and challenges.

Gaipa G, Buracchi C, Biondi A.

Expert Rev Mol Diagn. 2018 Sep;18(9):775-787. doi: 10.1080/14737159.2018.1504680. Epub 2018 Aug 2. Review.

PMID:
30047795
5.

Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation.

Trento C, Bernardo ME, Nagler A, Kuçi S, Bornhäuser M, Köhl U, Strunk D, Galleu A, Sanchez-Guijo F, Gaipa G, Introna M, Bukauskas A, Le Blanc K, Apperley J, Roelofs H, Van Campenhout A, Beguin Y, Kuball J, Lazzari L, Avanzini MA, Fibbe W, Chabannon C, Bonini C, Dazzi F.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2365-2370. doi: 10.1016/j.bbmt.2018.07.015. Epub 2018 Jul 20.

6.

Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study.

Cerrito MG, De Giorgi M, Pelizzoni D, Bonomo SM, Digiacomo N, Scagliotti A, Bugarin C, Gaipa G, Grassilli E, Lavitrano M, Giovannoni R, Bidoli P, Cazzaniga ME.

Oncotarget. 2018 Jun 8;9(44):27448-27459. doi: 10.18632/oncotarget.25422. eCollection 2018 Jun 8.

7.

SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia.

Sarno J, Savino AM, Buracchi C, Palmi C, Pinto S, Bugarin C, Jager A, Bresolin S, Barber RC, Silvestri D, Israeli S, Dyer MJS, Cazzaniga G, Nolan GP, Biondi A, Davis KL, Gaipa G.

Oncotarget. 2018 May 1;9(33):22872-22885. doi: 10.18632/oncotarget.25089. eCollection 2018 May 1.

8.

Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia.

Sędek Ł, Theunissen P, Sobral da Costa E, van der Sluijs-Gelling A, Mejstrikova E, Gaipa G, Sonsala A, Twardoch M, Oliveira E, Novakova M, Buracchi C, van Dongen JJM, Orfao A, van der Velden VHJ, Szczepański T; EuroFlow Consortium.

J Immunol Methods. 2018 Mar 9. pii: S0022-1759(17)30126-6. doi: 10.1016/j.jim.2018.03.005. [Epub ahead of print]

PMID:
29530508
9.

Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse.

Good Z, Sarno J, Jager A, Samusik N, Aghaeepour N, Simonds EF, White L, Lacayo NJ, Fantl WJ, Fazio G, Gaipa G, Biondi A, Tibshirani R, Bendall SC, Nolan GP, Davis KL.

Nat Med. 2018 May;24(4):474-483. doi: 10.1038/nm.4505. Epub 2018 Mar 5.

10.

Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia.

Lhermitte L, Mejstrikova E, van der Sluijs-Gelling AJ, Grigore GE, Sedek L, Bras AE, Gaipa G, Sobral da Costa E, Novakova M, Sonneveld E, Buracchi C, de Sá Bacelar T, Te Marvelde JG, Trinquand A, Asnafi V, Szczepanski T, Matarraz S, Lopez A, Vidriales B, Bulsa J, Hrusak O, Kalina T, Lecrevisse Q, Martin Ayuso M, Brüggemann M, Verde J, Fernandez P, Burgos L, Paiva B, Pedreira CE, van Dongen JJM, Orfao A, van der Velden VHJ.

Leukemia. 2018 Apr;32(4):874-881. doi: 10.1038/leu.2017.313. Epub 2017 Nov 1.

11.

Redirecting T cells with Chimeric Antigen Receptor (CAR) for the treatment of childhood acute lymphoblastic leukemia.

Biondi A, Magnani CF, Tettamanti S, Gaipa G, Biagi E.

J Autoimmun. 2017 Dec;85:141-152. doi: 10.1016/j.jaut.2017.08.003. Epub 2017 Aug 24. Review.

PMID:
28843422
12.

Intravenous infusion of human bone marrow mesenchymal stromal cells promotes functional recovery and neuroplasticity after ischemic stroke in mice.

Sammali E, Alia C, Vegliante G, Colombo V, Giordano N, Pischiutta F, Boncoraglio GB, Barilani M, Lazzari L, Caleo M, De Simoni MG, Gaipa G, Citerio G, Zanier ER.

Sci Rep. 2017 Jul 31;7(1):6962. doi: 10.1038/s41598-017-07274-w.

13.

Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation.

Introna M, Lussana F, Algarotti A, Gotti E, Valgardsdottir R, Micò C, Grassi A, Pavoni C, Ferrari ML, Delaini F, Todisco E, Cavattoni I, Deola S, Biagi E, Balduzzi A, Rovelli A, Parma M, Napolitano S, Sgroi G, Marrocco E, Perseghin P, Belotti D, Cabiati B, Gaipa G, Golay J, Biondi A, Rambaldi A.

Biol Blood Marrow Transplant. 2017 Dec;23(12):2070-2078. doi: 10.1016/j.bbmt.2017.07.005. Epub 2017 Jul 13.

14.

Simultaneous overexpression of human E5NT and ENTPD1 protects porcine endothelial cells against H2O2-induced oxidative stress and cytotoxicity in vitro.

Chisci E, De Giorgi M, Zanfrini E, Testasecca A, Brambilla E, Cinti A, Farina L, Kutryb-Zajac B, Bugarin C, Villa C, Grassilli E, Combi R, Gaipa G, Cerrito MG, Rivolta I, Smolenski RT, Lavitrano M, Giovannoni R.

Free Radic Biol Med. 2017 Jul;108:320-333. doi: 10.1016/j.freeradbiomed.2017.03.038. Epub 2017 Apr 5.

15.

The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL.

Savino AM, Sarno J, Trentin L, Vieri M, Fazio G, Bardini M, Bugarin C, Fossati G, Davis KL, Gaipa G, Izraeli S, Meyer LH, Nolan GP, Biondi A, Te Kronnie G, Palmi C, Cazzaniga G.

Leukemia. 2017 Nov;31(11):2365-2375. doi: 10.1038/leu.2017.93. Epub 2017 Mar 23.

PMID:
28331226
16.

AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia.

Dworzak MN, Buldini B, Gaipa G, Ratei R, Hrusak O, Luria D, Rosenthal E, Bourquin JP, Sartor M, Schumich A, Karawajew L, Mejstrikova E, Maglia O, Mann G, Ludwig WD, Biondi A, Schrappe M, Basso G; International-BFM-FLOW-network.

Cytometry B Clin Cytom. 2018 Jan;94(1):82-93. doi: 10.1002/cyto.b.21518. Epub 2017 Feb 21.

17.

Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia.

Theunissen P, Mejstrikova E, Sedek L, van der Sluijs-Gelling AJ, Gaipa G, Bartels M, Sobral da Costa E, Kotrová M, Novakova M, Sonneveld E, Buracchi C, Bonaccorso P, Oliveira E, Te Marvelde JG, Szczepanski T, Lhermitte L, Hrusak O, Lecrevisse Q, Grigore GE, Froňková E, Trka J, Brüggemann M, Orfao A, van Dongen JJ, van der Velden VH; EuroFlow Consortium.

Blood. 2017 Jan 19;129(3):347-357. doi: 10.1182/blood-2016-07-726307. Epub 2016 Nov 30.

18.

CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia.

Palmi C, Savino AM, Silvestri D, Bronzini I, Cario G, Paganin M, Buldini B, Galbiati M, Muckenthaler MU, Bugarin C, Della Mina P, Nagel S, Barisone E, Casale F, Locatelli F, Lo Nigro L, Micalizzi C, Parasole R, Pession A, Putti MC, Santoro N, Testi AM, Ziino O, Kulozik AE, Zimmermann M, Schrappe M, Villa A, Gaipa G, Basso G, Biondi A, Valsecchi MG, Stanulla M, Conter V, Te Kronnie G, Cazzaniga G.

Oncotarget. 2016 Sep 13;7(37):59260-59272. doi: 10.18632/oncotarget.10610.

19.

Development of advanced therapies in Italy: Management models and sustainability in six Italian cell factories.

Gaipa G, Introna M, Golay J, Nolli ML, Vallanti G, Parati E, Giordano R, Romagnoli L, Melazzini M, Biondi A, Biagi E.

Cytotherapy. 2016 Apr;18(4):481-6. doi: 10.1016/j.jcyt.2016.01.002.

PMID:
26971677
20.

The TGF-β pathway is activated by 5-fluorouracil treatment in drug resistant colorectal carcinoma cells.

Romano G, Santi L, Bianco MR, Giuffrè MR, Pettinato M, Bugarin C, Garanzini C, Savarese L, Leoni S, Cerrito MG, Leone BE, Gaipa G, Grassilli E, Papa M, Lavitrano M, Giovannoni R.

Oncotarget. 2016 Apr 19;7(16):22077-91. doi: 10.18632/oncotarget.7895.

21.

Simultaneous Overexpression of Functional Human HO-1, E5NT and ENTPD1 Protects Murine Fibroblasts against TNF-α-Induced Injury In Vitro.

Cinti A, De Giorgi M, Chisci E, Arena C, Galimberti G, Farina L, Bugarin C, Rivolta I, Gaipa G, Smolenski RT, Cerrito MG, Lavitrano M, Giovannoni R.

PLoS One. 2015 Oct 29;10(10):e0141933. doi: 10.1371/journal.pone.0141933. eCollection 2015.

22.

Full GMP-compliant validation of bone marrow-derived human CD133(+) cells as advanced therapy medicinal product for refractory ischemic cardiomyopathy.

Belotti D, Gaipa G, Bassetti B, Cabiati B, Spaltro G, Biagi E, Parma M, Biondi A, Cavallotti L, Gambini E, Pompilio G.

Biomed Res Int. 2015;2015:473159. doi: 10.1155/2015/473159. Epub 2015 Oct 1.

23.

Peripheral blood cells from children with RASopathies show enhanced spontaneous colonies growth in vitro and hyperactive RAS signaling.

Gaipa G, Bugarin C, Cianci P, Sarno J, Bonaccorso P, Biondi A, Selicorni A.

Blood Cancer J. 2015 Jul 17;5:e324. doi: 10.1038/bcj.2015.52.

24.

Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.

Karawajew L, Dworzak M, Ratei R, Rhein P, Gaipa G, Buldini B, Basso G, Hrusak O, Ludwig WD, Henze G, Seeger K, von Stackelberg A, Mejstrikova E, Eckert C.

Haematologica. 2015 Jul;100(7):935-44. doi: 10.3324/haematol.2014.116707. Epub 2015 May 22.

25.

Failure of interferon-γ pre-treated mesenchymal stem cell treatment in a patient with Crohn's disease.

Taddio A, Tommasini A, Valencic E, Biagi E, Decorti G, De Iudicibus S, Cuzzoni E, Gaipa G, Badolato R, Prandini A, Biondi A, Ventura A.

World J Gastroenterol. 2015 Apr 14;21(14):4379-84. doi: 10.3748/wjg.v21.i14.4379.

26.

Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B-cell precursor acute lymphoblastic leukemia.

Bugarin C, Sarno J, Palmi C, Savino AM, te Kronnie G, Dworzak M, Shumich A, Buldini B, Maglia O, Sala S, Bronzini I, Bourquin JP, Mejstrikova E, Hrusak O, Luria D, Basso G, Izraeli S, Biondi A, Cazzaniga G, Gaipa G; I-BFM study group.

Haematologica. 2015 Jun;100(6):e229-32. doi: 10.3324/haematol.2014.114447. Epub 2015 Apr 10. No abstract available.

27.

Recurrent ETNK1 mutations in atypical chronic myeloid leukemia.

Gambacorti-Passerini CB, Donadoni C, Parmiani A, Pirola A, Redaelli S, Signore G, Piazza V, Malcovati L, Fontana D, Spinelli R, Magistroni V, Gaipa G, Peronaci M, Morotti A, Panuzzo C, Saglio G, Usala E, Kim DW, Rea D, Zervakis K, Viniou N, Symeonidis A, Becker H, Boultwood J, Campiotti L, Carrabba M, Elli E, Bignell GR, Papaemmanuil E, Campbell PJ, Cazzola M, Piazza R.

Blood. 2015 Jan 15;125(3):499-503. doi: 10.1182/blood-2014-06-579466. Epub 2014 Oct 24.

28.

Flow diagnostics essential code: a simple and brief format for the summary of leukemia phenotyping.

Hrušák O, Basso G, Ratei R, Gaipa G, Luria D, Mejstříková E, Karawajew L, Buldini B, Rozenthal E, Bourquin JP, Kalina T, Sartor M, Dworzak MN; AIEOP-BFM Flow Network.

Cytometry B Clin Cytom. 2014 Jul;86(4):288-91.

PMID:
25057519
29.

The CD133+ cell as advanced medicinal product for myocardial and limb ischemia.

Bongiovanni D, Bassetti B, Gambini E, Gaipa G, Frati G, Achilli F, Scacciatella P, Carbucicchio C, Pompilio G.

Stem Cells Dev. 2014 Oct 15;23(20):2403-21. doi: 10.1089/scd.2014.0111. Epub 2014 Aug 20. Review.

PMID:
25014242
30.

Inhibition of mesenchymal stromal cells by pre-activated lymphocytes and their culture media.

Valencic E, Loganes C, Cesana S, Piscianz E, Gaipa G, Biagi E, Tommasini A.

Stem Cell Res Ther. 2014 Jan 9;5(1):3. doi: 10.1186/scrt392.

31.

Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients.

Introna M, Lucchini G, Dander E, Galimberti S, Rovelli A, Balduzzi A, Longoni D, Pavan F, Masciocchi F, Algarotti A, Micò C, Grassi A, Deola S, Cavattoni I, Gaipa G, Belotti D, Perseghin P, Parma M, Pogliani E, Golay J, Pedrini O, Capelli C, Cortelazzo S, D'Amico G, Biondi A, Rambaldi A, Biagi E.

Biol Blood Marrow Transplant. 2014 Mar;20(3):375-81. doi: 10.1016/j.bbmt.2013.11.033. Epub 2013 Dec 7.

32.

Validation of flow cytometric phospho-STAT5 as a diagnostic tool for juvenile myelomonocytic leukemia.

Hasegawa D, Bugarin C, Giordan M, Bresolin S, Longoni D, Micalizzi C, Ramenghi U, Bertaina A, Basso G, Locatelli F, Biondi A, Te Kronnie G, Gaipa G.

Blood Cancer J. 2013 Nov 15;3:e160. doi: 10.1038/bcj.2013.56.

33.

Allogeneic mesenchymal stem cell infusion for the stabilization of focal segmental glomerulosclerosis.

Belingheri M, Lazzari L, Parazzi V, Groppali E, Biagi E, Gaipa G, Giordano R, Rastaldi MP, Croci D, Biondi A, Rebulla P, Edefonti A, Ghio L.

Biologicals. 2013 Nov;41(6):439-45. doi: 10.1016/j.biologicals.2013.09.004. Epub 2013 Oct 14.

PMID:
24135082
34.

Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.

Gaipa G, Basso G, Biondi A, Campana D.

Cytometry B Clin Cytom. 2013 Nov-Dec;84(6):359-69. doi: 10.1002/cyto.b.21101. Epub 2013 Jun 26. Review.

35.

Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.

Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A, Antolini L, Mologni L, Donadoni C, Papaemmanuil E, Schnittger S, Kim DW, Boultwood J, Rossi F, Gaipa G, De Martini GP, di Celle PF, Jang HG, Fantin V, Bignell GR, Magistroni V, Haferlach T, Pogliani EM, Campbell PJ, Chase AJ, Tapper WJ, Cross NC, Gambacorti-Passerini C.

Nat Genet. 2013 Jan;45(1):18-24. doi: 10.1038/ng.2495. Epub 2012 Dec 9.

36.

Mesenchymal stromal cells do not increase the risk of viral reactivation nor the severity of viral events in recipients of allogeneic stem cell transplantation.

Lucchini G, Dander E, Pavan F, Di Ceglie I, Balduzzi A, Perseghin P, Gaipa G, Algarotti A, Introna M, Rambaldi A, Rovelli A, Biondi A, Biagi E, D'Amico G.

Stem Cells Int. 2012;2012:690236. doi: 10.1155/2012/690236. Epub 2012 May 30.

37.

Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia.

Gaipa G, Cazzaniga G, Valsecchi MG, Panzer-Grümayer R, Buldini B, Silvestri D, Karawajew L, Maglia O, Ratei R, Benetello A, Sala S, Schumich A, Schrauder A, Villa T, Veltroni M, Ludwig WD, Conter V, Schrappe M, Biondi A, Dworzak MN, Basso G.

Haematologica. 2012 Oct;97(10):1582-93. doi: 10.3324/haematol.2011.060426. Epub 2012 May 11.

38.

Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring.

Dander E, Lucchini G, Vinci P, Introna M, Masciocchi F, Perseghin P, Balduzzi A, Bonanomi S, Longoni D, Gaipa G, Belotti D, Parma M, Algarotti A, Capelli C, Golay J, Rovelli A, Rambaldi A, Biondi A, Biagi E, D'Amico G.

Leukemia. 2012 Jul;26(7):1681-4. doi: 10.1038/leu.2011.384. Epub 2012 Jan 13. No abstract available.

PMID:
22289986
39.

Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemia.

Cazzaniga G, Valsecchi MG, Gaipa G, Conter V, Biondi A.

Br J Haematol. 2011 Oct;155(1):45-52. doi: 10.1111/j.1365-2141.2011.08795.x. Epub 2011 Aug 4.

PMID:
21812769
40.

Autologous purified peripheral blood SCT in childhood low-risk relapsed ALL.

Balduzzi A, Bonanomi S, Valsecchi MG, Gaipa G, Perseghin P, Songia S, Maglia O, Rossi V, Motta S, Di Maio L, Dassi M, Uderzo C, Conter V, Henze G, von Stackelberg A, Rovelli A, Biondi A, Galimberti S.

Bone Marrow Transplant. 2011 Feb;46(2):217-26. doi: 10.1038/bmt.2010.85. Epub 2010 Apr 26.

PMID:
20421865
41.

Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population.

Lucchini G, Introna M, Dander E, Rovelli A, Balduzzi A, Bonanomi S, Salvadè A, Capelli C, Belotti D, Gaipa G, Perseghin P, Vinci P, Lanino E, Chiusolo P, Orofino MG, Marktel S, Golay J, Rambaldi A, Biondi A, D'Amico G, Biagi E.

Biol Blood Marrow Transplant. 2010 Sep;16(9):1293-301. doi: 10.1016/j.bbmt.2010.03.017. Epub 2010 Mar 27.

42.

CD11b is a therapy resistance- and minimal residual disease-specific marker in precursor B-cell acute lymphoblastic leukemia.

Rhein P, Mitlohner R, Basso G, Gaipa G, Dworzak MN, Kirschner-Schwabe R, Hagemeier C, Stanulla M, Schrappe M, Ludwig WD, Karawajew L, Ratei R.

Blood. 2010 May 6;115(18):3763-71. doi: 10.1182/blood-2009-10-247585. Epub 2010 Mar 12.

43.

Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group.

Dworzak MN, Gaipa G, Schumich A, Maglia O, Ratei R, Veltroni M, Husak Z, Basso G, Karawajew L, Gadner H, Biondi A.

Cytometry B Clin Cytom. 2010 May;78(3):147-53. doi: 10.1002/cyto.b.20516.

44.

Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.

Basso G, Veltroni M, Valsecchi MG, Dworzak MN, Ratei R, Silvestri D, Benetello A, Buldini B, Maglia O, Masera G, Conter V, Arico M, Biondi A, Gaipa G.

J Clin Oncol. 2009 Nov 1;27(31):5168-74. doi: 10.1200/JCO.2008.20.8934. Epub 2009 Oct 5.

PMID:
19805690
45.

GMP-based CD133(+) cells isolation maintains progenitor angiogenic properties and enhances standardization in cardiovascular cell therapy.

Gaipa G, Tilenni M, Straino S, Burba I, Zaccagnini G, Belotti D, Biagi E, Valentini M, Perseghin P, Parma M, Campli CD, Biondi A, Capogrossi MC, Pompilio G, Pesce M.

J Cell Mol Med. 2010 Jun;14(6B):1619-34. doi: 10.1111/j.1582-4934.2009.00854.x. Epub 2009 Jul 20.

46.

A case of Philadelphia Positive Acute Lymphoblastic Leukaemia with three different phenotypic lineage, each one presenting the same BCR-ABL hybrid transcript.

Parma M, Colnaghi F, Colombo A, Elli E, Rossi F, Gaipa G, Rossi V, Casaroli I, Biondi A, Pogliani EM.

Leuk Res. 2009 Nov;33(11):e175-7. doi: 10.1016/j.leukres.2009.04.030. Epub 2009 May 23. No abstract available.

PMID:
19476999
47.

Regulatory T cells and extracorporeal photochemotherapy: correlation with clinical response and decreased frequency of proinflammatory T cells.

Di Biaso I, Di Maio L, Bugarin C, Gaipa G, Dander E, Balduzzi A, Parma M, D'Amico G, Perseghin P, Biondi A, Biagi E.

Transplantation. 2009 May 15;87(9):1422-5. doi: 10.1097/TP.0b013e3181a27a5d.

PMID:
19424046
48.

Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction.

Ratei R, Basso G, Dworzak M, Gaipa G, Veltroni M, Rhein P, Biondi A, Schrappe M, Ludwig WD, Karawajew L; AIEOP-BFM-FCM-MRD-Study Group.

Leukemia. 2009 Mar;23(3):528-34. doi: 10.1038/leu.2008.324. Epub 2008 Nov 20.

PMID:
19020543
49.

Aberrant GM-CSF signal transduction pathway in juvenile myelomonocytic leukemia assayed by flow cytometric intracellular STAT5 phosphorylation measurement.

Gaipa G, Bugarin C, Longoni D, Cesana S, Molteni C, Faini A, Timeus F, Zecca M, Biondi A.

Leukemia. 2009 Apr;23(4):791-3. doi: 10.1038/leu.2008.265. Epub 2008 Oct 2. No abstract available.

PMID:
18830265
50.

CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy.

Dworzak MN, Schumich A, Printz D, Pötschger U, Husak Z, Attarbaschi A, Basso G, Gaipa G, Ratei R, Mann G, Gadner H.

Blood. 2008 Nov 15;112(10):3982-8. doi: 10.1182/blood-2008-06-164129. Epub 2008 Sep 9.

Supplemental Content

Support Center